Thursday, March 30, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

Emergent’s Nerve Agent Antidote Platform Selected for DoD Development

by Global Biodefense Staff
February 17, 2016
Biodefense News - Industry Updates

Emergent BioSolutions Inc. today announced that the company’s ruggedized, military-grade auto-injector platform has been selected by the U.S. Department of Defense (DoD) and Battelle to be tested against and developed to U.S. military specifications as a platform for nerve agent antidote delivery.

Emergard, launched by the company in August 2015, was selected from among several commercially available auto-injector devices, is designed to be transported, stored, and operated in a military environment and to ensure needle penetration and successful injection through chemical protective gear.

Development and testing of Emergard is expected to be completed in 2016 and, if successful, could lead to Emergard’s future procurement for U.S. military and emergency responder use.

“We are pleased that our Emergard platform has been selected by DoD and Battelle for testing and development to address U.S. military auto-injector needs,” said Adam Havey, executive vice president and president, biodefense division of Emergent BioSolutions. “The Emergard platform, which is designed for intramuscular self-injection of antidotes and other emergency response medical treatments for nerve agents and other chemical threats, is another example of Emergent’s commitment to protecting lives and being a global leader in the development and manufacture of medical countermeasures that address biological and chemical threats as well as emerging infectious diseases.”

The testing and development of Emergard will be performed under a subcontract with Battelle, which in turn has a prime contract with DoD. This contract is supported by the Defense Technical Information Center, which serves the DoD community as the largest central resource for DoD and government-funded research, development, technical, and engineering information. Emergard is not approved by the U.S. Food and Drug Administration.

Emergard is a trademarked, protected term by Emergent Biosolutions.

Tags: AwardsBattelle

Related Posts

Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC